Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5885_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
21 Мб
Скачать
74
https://t.me/medicina_free
In Vitro Potential Anticancer Effects of Ursolic Acid
Cell Line Cytotoxicity Evaluation Effects References
Method (Dose and
Incubation Time)
HepG2, Hep3B, Huh7, and MTT assay (2, 4 and 8 Induces Yan et al., HA22T cell lines, L-02 cell μmol/l UA for 48 h) apoptosis 2010 (human normal liver cell line)
BGC-803 cell and MTT assay (10–60 μM for Inhibits Wang et hepatocellular carcinoma 12, 24, 36 and 48 h) proliferation, al., 2013 cell line H22 Induces
SW480 and LoVo Human MTT assay (20 and 40 μM Inhibits Weng et colon cancer cell lines for 48 h) FITC-annexin V/ proliferation, al., 2014
GBC-SD and SGC-996 MTT assay (40–70 μmol/l Antitumoral Nam and (human cell lines) for 24, 48 or 72 h) effects Kim, 2013
DNA fragmentation (2, 4
and 8 μmol/l UA for 48 h)
PI (20 and 40 μM for 48 h) Induces
FITC-annexin V (40–70
μmol/l for 36 h)
Biomarkers as Targeted Herbal Drug Discovery
apoptosis
apoptosis
SW480 (human-colon MTT assay (1–32 μM for Induces Lin et al., adenocarcinoma cells) 24 h) DNA fragmentation apoptosis 2014
(1–8 μM for 24 h)
U937 (human leukemia NBT reduction assay (30 Differentiation- Park et al., cells) μmol/l for 4 days) inducing agent 2013
for leukemia therapy
PC-3, DU145, LNCaP MTT assay (5–80 μM for Induces Kim et al., (prostate cancer cells), Raw 24 h) DAPI (30 μM for apoptosis 2011
264.7 (leukemic monocyte- 24 h) macrophage cells) HEK293 (human embryonic kidney
293) MDA-MB-231, human MTT assay (5–100 μM for Induces Shin and
breast cancer cell line 24 or 48 h) apoptosis Park, 2013
FACS (40 μM for 24 or
48 h)
LNCaP, PC3, DU145, MTT assay (30 μM for Induces Zheng et A549, MCF7, HCT116 and 24 h) apoptosis al., 2013 HeLa cells
T24 and BIU-87 lines MTT assay (219 μM for Induces Zheng et (human bladder cancer cell) 72 h) FACS/PI (219 μM apoptosis al., 2012
for 48 h)
75 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
(Continued)
Cell Line Cytotoxicity Evaluation Effects References
Method (Dose and
Incubation Time)
T24 (human bladder cancer MTT assay (6.25–400 μg/ Contributes Xavier et cell) mL for 24 h; 50, 100 and to growth al., 2013
200 μg/mL for 24 and 48 inhibition and h) apoptosis
FACS/PI (50, 100 and 200
μg/mL for 24 h)
HCT15 and CO115 (human TUNEL assay (4 μM for Induces Limami et colon carcinoma-derived 48 h) apoptosis, al., 2012 cells)
PI (4 μM for 48 h)
Autophagy
modulation HT-29 (human colorectal) DNA fragmentation (25 Induces Shin et al., DU145 (human prostate
μM for 48 h) apoptosis 2012
carcinoma cells) PC3 and DU145 cells MTT assay (10–40 μM for Induces Huang et
24 h) DNA fragmentation apoptosis al., 2011
(30 and 40 μM for 24 h) PI (30 and 40 μM for 24 h)
HNBE (human normal lung MTT assay (2, 4, 8 and 16 cells) A549, H3255, and μmol/l for 48 h) Calu-6 (lung cancer cells)
LDH assay (2, 4, 8 and 16
μmol/l for 48 h)
Inhibition Limami et
of cell al., 2011
proliferation,
invasion, and
migration
DNA fragmentation (2, 4,
8 and 16 μmol/l for 48 h)
HT-29 and HCT116 (human DNA fragmentation (20 Induces Messner et colorectal cell line) and 30 μM for 24 and 48 apoptosis al., 2011
h)
DAPI (30 μM for 48 h)
HUVECs (isolation and XTT assay (3.125–50 μM Inhibits Bari et al., culture of human umbilical for 24 and 48 h) endothelial 2017 vein endothelial cells)
Annexin V-FITC/PI (6.25
and 12.5 μM for 6, 12, 18,
24 and 48 h)
DAPI: 4′,6-Diamidino-2-phenylindole; FACS: Fluorescence-activated cell sorting; FITC: Fluorescein
isothiocyanate; GBC-SD: Cell line human; HeLa: Cell line human (epitheloid cervix carcinoma); HNBE: Normal human bronchial epithelial cells; HUVEC: Human umbilical vein endothelial cells; LDH: Lactate dehydrogenase; LoVo: Cells line human colon; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5­diphenyltetrazolium bromide; NBT: Nitroblue tetrazolium; PI: Propidium iodide; TUNEL: Transferase dUTP nick end labeling; UA: Ursolic acid; XTT: 2,3-bis- (2-methoxy-4-nitro-5-sulfophenyl)-2H­tetrazolium-5-carboxanilida.
proliferation,
Inducer of
endothelial cell
death
76
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
repair materials for treating efficaciously bone defects (Rezwan et al., 2006). Excellent biocompatibility, osteoconductivity, and bioactivity should be exhib­ited by optimal bone repair materials (Kim et al., 2016; Chen et al., 2018).
UA is rarely employed for bone tissue regeneration as the few studies were
performed in the eld of bone tissue repair. Most importantly, osteoblast differ­entiation also involves the Smad signaling pathway. The release prole of UA
from the suitable incorporated dosage form remarkably increased the alkaline phosphatase (ALP) activity, osteogenic differentiation-related gene type I collagen, runt-related transcription factor 2 expression, and osteoblast-associ­ated protein expression. Moreover, the results of micro-CT images, observations from histomorphological data demonstrated that the UA in a suitable dosage form can improve new bone formation ability. Therefore, the UA can be used as novel bone tissue engineering materials by incorporating into a suitable matrix.

Nanotechnology has emerged as an efficient tool to address issues of solubility, stability, and oral bioavailability (Valdes et al., 2014). Indeed, a nanosystem­based delivery of drugs, photosensitizers, biomolecules, phytochemicals, and other compounds of interest presents numerous advantages to traditional delivery methods, including facilitated transport across biological barriers, enhanced bioavailability when water solubility is poor, targeted delivery, protection from biological and/or environmental degradation (particularly for sensitive compounds) and controlled release (Morales et al., 2015; Li et al., 2015). Recent improvements in therapeutic efficiency through the use of nanotechnology have gained attention due to enhanced phytochemical delivery to tumors and cancer cells (Gao et al., 2014; Bertrand et al., 2014; Amiji, 2006; Wang et al., 2014).
In oncology, numerous potential benets, such as protecting the entrapped
therapeutic drug from degradation, reducing toxicity to normal cells, modi-
fying the pharmacokinetics and tissue distribution prole to increase drug
distribution in the tumor are offered by targeted drug delivery systems. Preventing the side effects of clinical formulations for improving solubility; and increasing cellular uptake and internalization in cancer cells (Bertrand et al., 2014). Several delivery nanosystems like liposomes, nanoemulsions, micelles, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), etc., have been used to enhance the physicochemical nature of phytochemicals. These are the most commonly used nanosystems and can
77 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
be administered orally, intravenously, intraperitoneally, or transdermally, among other routes (Pattni et al., 2015).

In vesicles formed by nonionic surfactants (niosomes) and phospholipids (liposomes), the different regions (i.e., aqueous medium, interface, and hydrocarbon chains) allow interactions with a wide variety of substrates (Uchegbuk and Florence, 1995; Sandoval et al., 2015). For example, electro­statically charged species would bind to the interface, whereas hydrophobic substrates would locate inside the bilayer. Specifically, many advantages for drug delivery, include good biocompatibility, biodegradability, low toxicity, and a controlled release of the entrapped drug are represented by liposomes (Han et al., 1997) (Figure 4.2).
 Basic structure of liposomes.

Regarding UA incorporation into the liposomes Han et al. was the first who studied the effect of triterpenes on membrane fluidity, with 1,2-dipal­mitoyl-sn-glycerol-3-phosphocholine (DPPC) liposomes. The study wants to find that UA has a strong condensing effect on the liposomal membrane not only in the liquid-crystalline state but also in the crystal­line state. UA displays fewer effects in decreasing the fluidity of the
78
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
liquid-crystalline liposomal membrane as well as higher membrane-stabi­lizing effects are comparable with another triterpenes and natural products (Both et al., 2002).
In another study, injection formed liposomes with a low concentration of UA (3 mM) was incorporated into a gel of Carbopol 981. This study reported that UA incorporation into liposomes increased both the ceramide content of cultured normal human epidermal keratinocytes and the collagen content of
cultured normal human dermal broblasts (Caldeira et al., 2013).
Caldeira et al. proposed the pH-sensitive liposomes containing UA. This was prepared with the lipid hydration method in a total lipid concentration of 20 mM using the same amount of dioleoyl-phosphatidyl-ethanolamine and cholesteryl-hemisuccinate and di-stearoyl-phosphatidyl-ethanolamine­polyethyleneglycol (PEG) 2000 in very low concentration. All materials should be dissolved in chloroform, with a UA equivalent at 0.1% or 0.05% (w/v). Then the whole solution will be added to the lipid solution. Approxi­mately 88% of the vesicles were < 300 nm, had almost neutral surface charges, showed no effects on stability, and had a UA entrapment of 0.77 ±
0.01 mg/mL which proves that UA can be successfully incorporated into it (Yang et al., 2014).
A recent study of Yang et al. reported the antitumor effects of a
folate-targeted UA stealth liposome prepared by the thin lm dispersed
hydration method. The lipid compositions were soybean phosphatidyl­choline/CHOL/monomethoxy polyethylene glycol 2000-distearoyl­phosphatidyl-ethanolamine and soybean phosphatidylcholine/CHOL/ mPEG-DSPE2000/folate-PEG cholesteryl hemisuccinate, with a 1: 20 (w/w) UA to lipid ratio. The lipid suspension was then extruded to produce unilamellar vesicles. Liposome characterizations were similar in both cases, with mean size distributions (150160 nm), potentials (–23.15 and
–21.24 mV), and UA entrapment efciencies (86.7 and 88.9%) (Qian et
al., 2015). The result determines that UA can be successfully incorporated into these matrixes.

In vitro and in vivo models both have been used to assess the anti-inflamma­tory, anti-proliferative, and pro-apoptotic effects of triterpenoids in relation to potential anticancer activities.
The effect of pH-sensitive liposome-UA on breast and prostate cancer cell line viabilities were also studied by MTT assays, revealing that IC50
79 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
values obtained after liposome-UA treatment (48 h) were signicantly lower
than IC50 values obtained after free-form UA treatment of MDA-MB-231 cancer cells (Yang et al., 2014).
Regarding in vivo studies, Yang et al. evaluated PEGylated liposome and
folate-receptor-targeted liposome antitumor efcacies using the human KB
tumor xenograft model in female Balb/c nude mice. The obtained results demonstrated that free-form UA did not decrease tumor growth, which was in contrast to mice treated with folate-receptor-targeted-liposome-UA, which resulted in a 55% reduction in tumor volume compared with PBS-treated mice (Qian et al., 2015).
Qian et al. recently examined the safety and activity of UA liposomes against tumors in 20 subjects of age 18–75, in whom the presence of advanced
solid tumors had already conrmed by cytological or histological data. All
subjects received intravenously administered UA liposomes at doses of 56,
2
74, and 98 mg/m
for 14 consecutive days over a 21-day time period. All
the subjects were evaluated at the tolerability and toxicity scale. The results
demonstrating the safety prole of UA liposome treatment particularly for
subjects with advanced solid tumors. Indeed, 60% of patients achieved stable disease status after two treatment cycles (Wang et al., 2013).
Wang et al. evaluated the toxicity and single-dose PKs of intravenous UA liposomes. All subjects received a single-dose of UA liposomes (11, 22, 37, 56, 74, 98, and 130 mg/m
2
) administered as a 4 h intravenous infusion. The clinical
data reported, for the rst time, that the UA liposome had manageable toxici­ties, with a maximum tolerated a dose of 98 mg/m
2
encountered at 74, 98, and 130 mg/m
, and consisted of hepatotoxicity and
2
. Dose-limiting toxicity was
diarrhea. The single-dose pharmacokinetic parameters revealed a linear rela­tionship between Cmax, AUC024 h (Merisko-Liversidge et al., 2003).

For years the use of nanocarrier-mediated drug delivery systems into the improvement of the therapeutic activity and safety of drugs. Formula­tions for poorly water-soluble drugs like nanoliposome is a promising approach (Zhu et al., 2013). The new technologies for the encapsulation and delivery of bioactive agents are nanoliposome, or submicron bilayer lipid vesicle. The immense list of bioactive material ranging from phar­maceuticals to cosmetics and nutraceuticals can be incorporated into nanoliposomes. Due to the nanosize along with their biocompatibility and biodegradability, their, nanoliposomes have demonstrated their
80
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
potential applications in numerous fields. By improving the solubility, bioavailability, in vitro, and in vivo stability, along with the prevention of unwanted interactions with other molecules, nanoliposomes are able to enhance the performance of bioactive agents. Cell-specific targeting is an another advantage of nanoliposomes, which is a prerequisite to attain drug concentrations, required for obtaining maximum therapeutic efficacy in the target site while minimizing adverse effects on healthy cells and tissues. It is used mainly in cosmetics, food technology, and agriculture and also including nano-therapy like diagnosis, cancer therapy and gene delivery (Figure 4.3).

Thus, for the first time development of UA nanoliposomes (UANL) were happening in the People’s Republic of China. Because due to bypassing the stomach by nanoparticles the bioavailability of UANL is considered to be improved at intravenous (IV) administration. Till date, a wide range of preclinical studies have been completed in China (Li, unpublished data, 2005). A further unpublished study has demonstrated the induced minimal toxic effects even with the long-term application by UAN L.

There are some studies which revealed the inhibition of the growth of various human cancer cells and nude mice xenografts by the nanoliposome­encapsulated UA. That the concept of the first entry of UANL into the stomach and intestines, followed by the rapid declination of its concentra­tions is suggested by tissue distribution experiments in mice. Conversely, the hepatic concentration of UA increases rapidly and exceeded the concentrations in the stomach and intestines at 4 hours after IV injection. The results demonstrated that UANL delivers UA to the liver, where it accumulates. Consequently, the drug disposition behavior changes in vivo, and the toxic and side effects of UA on other tissues is decreased (unpub­lished data). The antitumor activities and the minimal toxic effects of UA t were observed in preclinical studies and promoted the human clinical trials of UAN L.
81 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
 Basic structure of nanoliposome.
In Phase I, a nanoliposome study by Zhu et al., the UA nanoliposome exhibited a relatively linear pharmacokinetic behavior at dose levels between 37 and 98 mg/m
2
. Furthermore, there was no such evidence of drug accu­mulation with repeated doses of UANL was observed, and the intravenous infusion in patients with advanced tumors and by healthy volunteers was well tolerated (Alvarado et al., 2015).

Generally, nanoemulsions ranges from 10 to 1,000 nm are a system of colloidal particles in the submicron size range which enacting as a trans­porter of drug molecules. The surface of these carriers is amorphous and
82
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
lipophilic with a negative charge and with the solid spheres. To enhance site-specificity, magnetic nanoparticles can be used. They may enhance the therapeutic effectivity of the drug and customize the adverse effect and toxic reactions as a drug delivery system. The treatment of infection of the reticuloendothelial system (RES), enzyme replacement therapy in the liver, treatment of cancer, and vaccination are included as major appli­cations. An emulsion a biphasic system, is a thermodynamically unstable system, can be stabilized by the addition of an emulsifying agent (emul­gent or emulsifier), where one phase is dispersed into the other in the form of minute droplets ranging in diameter from 0.1 to 100 m. The dispersed phase is also known as the internal phase or the discontinuous phase while the outer phase is called dispersion medium, external phase, or continuous phase. The intermediate or interphase is an emulsifying agent. The termi­nology nanoemulsion’ is fine oil/water or water/oil dispersion also refers to a mini-emulsion which stabilized by an interfacial film of surfactant molecule having droplet size range 20,600 nm. Because of small size, of nanoemulsions are responsible for the transparent nature of it. There are three types of nanoemulsion as per their formulation technique:
1. Oil in water nanoemulsion: oil/nonaqueous phase are dispersed in the continuous aqueous phase;
2. Water in oil nanoemulsion: water droplets/aqueous phase are dispersed in the continuous oil phase; and
3. Bicontinuousnanoemulsions (Figure 4.4).

Alvarado et al. developed nanoemulsions using natural or synthetic UA mixtures. The nanoemulsion composition was obtained from pseudoter­nary phase diagrams composed of castor oil (oil phase, 20%), a 4:1 ratio mixture of Labrasol (surfactant), and Transcutol P (co-surfactant), propylene-glycol (aqueous phase, 20%) and OA/UA mixtures (0.2%). The sizes of droplets of nano-emulsions (NE) were 200.95 nm (p.i.
0.25) and 139.70 nm (p.i. 0.18), respectively which formed with a natural or synthetic UA mixture, ultimately shows great activity (Zhou et al., 2009).
83 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
 The basic structure of nanoemulsion droplets.

The existence of nanoparticles is only on the nanometer scale (i.e., below 100 nm in at least one dimension). The physical properties demonstrated by them are uniformity, conductance, or special optical properties. These are the most desirable properties in materials science and biology. Various nanopar­ticle drug delivery systems have been explored, including nanoparticles, nanospheres (NSs), nanocapsules (NCs), SLNs, and polymeric nanoparticles (Figure 4.5).